Clinical Considerations for Immuno-oncology (IO) Sequencing in Advanced Endometrial Cancer - Episode 10
Looking into the Future of Potential Studies Regarding IO Sequencing in Advanced EC
Panelists discuss how studies providing real-world data or large-scale randomized controlled trials (RCTs) on immuno-oncology (IO) sequencing, along with ongoing clinical trials in advanced endometrial cancer (EC), could drive changes in clinical practice by improving survival outcomes, refining patient selection, and informing treatment sequencing to enhance patient management strategies.
Summary for Physicians:
To drive changes in clinical practice regarding IO sequencing, studies that provide robust, real-world data or large-scale, RCTs would be the most compelling. Evidence demonstrating improved survival outcomes, reduced adverse effects, or more precise sequencing approaches for patient selection could directly influence treatment guidelines. Data showing the efficacy of combination therapies or sequencing strategies tailored to specific molecular profiles would also be valuable. Additionally, studies addressing cost-effectiveness and long-term benefits could help guide clinical decisions.
Regarding ongoing clinical trials, there are several studies in progress focused on advanced EC in the post-IO setting. These trials are investigating the efficacy of sequential therapies, combining immunotherapy with targeted treatments, and examining the optimal timing and sequencing of treatments following IO therapy. Results from these trials are expected to provide important insights into improving outcomes for patients with advanced EC, potentially leading to refined treatment regimens and better patient management strategies in the future.
Related Content:
